TY - JOUR T1 - Splenik Marjinal ZonLenfoma: Bir Olgu Sunumu TT - Splenik Marjinal ZonLenfoma: Bir Olgu Sunumu AU - Ergenç, Hasan AU - Varım, Ceyhun AU - Çekdemir, Demet AU - Yaylacı, Selçuk AU - Can, Fatma İnci AU - Tamer, Ali PY - 2015 DA - December JF - Journal of Human Rhythm PB - Ramazan AKDEMİR WT - DergiPark SN - 2149-455X SP - 119 EP - 122 VL - 1 IS - 3 LA - tr AB - Marjinal zonlenfomalar(MZL) sekonderlenfoidfolliküllerinmarjinalzonunda bulunan B lenfositlerden köken alan düşük dereceli lenfomalardır. Dünya Sağlık Örgütü (WHO)'nün sınıfl andırmasına göre marjinalzonlenfomalar, ekstranodal MALT lenfoma, splenikMZL ve nodalMZL olmak üzere 3 alt gruba ayrılır. Her 3 grubun kromozomal, genetik ve immünfenotipik yönden benzerlikleri vardır. Ekstranodal MALT lenfomalar kemik iliği ve periferik lenf nodu tutuluşunun çok nadir görüldüğü, uzun süre lokalize bir kitle olarak kalan, mukoza ile ilişkili lenfoid dokuyu (MALT) tutan yavaş seyirli lenfomalardır. Biz burada halsizlik, yorgunluk şikayeti ile başvuran ve marjinalzonlenfoma tanısı konan 84 yaşındaki bayan olgu sunmayı amaçladık KW - Splenik Marginal Zone Lenfoma KW - periferik yayma KW - kemik iliği akım sitometrisi N2 - Marginal zone lymphomas (MZL) represent a group of low grade lymphomas whose cells originate from B lymphocytes normally present in marginal zone of the secondary lymphoid follicles. According to World Healt Organization (WHO) classifi cation, MZL is described with three subtypes: extranodal MALT lymphoma, splenic MZL and nodal MZL. All threemarginal zone cell lymphomass hareimmuno-phenotypic, genetic and chromosomal similarities. Extranodal MALT lymphoma is an indolent disease that presents within volvement of mucosa associated lenfoid tissue (MALT) by a long-persistent local-ized mass with less frequent bone marrow and peripheral lymphnode involvement. We would like to report a 84 year old woman with splenic marginal zone lymphoma who presented with weak ness and fatigue CR - Joshi M, Sheikh H, Abbi K, Long S, Sharma K, Tulchinsky M, Epner E. CR - Marginalzonelymphoma: old, new, targeted, andepigenetictherapies. CR - TherAdvHematol2012;3:275-290. CR - ZinzaniPL. Themanyfaces of marginalzonelymphoma. CR - HematologyAmSocHematolEduc Program 2012;2012:426-432. CR - Arcaini L, Paulli M, Boveri E, Magrini U, Lazzarino M. Marginalzone-related CR - neoplasms of splenicandnodalorigin. Haematologica 2003;88:80-93. CR - Iannitto E, Ambrosetti A, Ammatuna E, Colosio M, Florena AM, Tripodo CR - C, et al. Splenicmarginalzonelymphomawithorwithoutvillouslymphocyt CR - es. Hematologic indingsandoutcomes in a series of 57 patients. Cancer CR - ;101:2050-2057. CR - Parry-Jones N, Matutes E, Gruszka-Westwood AM, SwansburyGJ, CR - WotherspoonAC, Catovsky D. Prognosticfeatures of spleniclymphomawith CR - villouslymphocytes: a report on 129 patients. Br J Haematol 2003;120:759- CR - Franco V, Florena AM, Iannitto E. Splenicmarginalzonelymphoma. Blood CR - ;101:2464-2472. CR - Thieblemont C, Felman P, Berger F, Dumontet C, Arnaud P, Hequet O, et CR - al. Treatment of splenicmarginalzone B-celllymphoma: an analysis of 81 CR - patients. ClinLymphoma 2002;3:41-47. CR - Salido M, Baro C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, et CR - al. Cytogenetic aberrationsandtheirprognosticvalue in a series of 330 CR - splenicmarginalzone B-celllymphomas: a multicenterstudy of theSplenic CR - B-Cell LymphomaGroup. Blood 2010;116:1479-1488. CR - Boveri E, Arcaini L, Merli M, Passamonti F, Rizzi S, Vanelli L, et al. Bone CR - marrow histology in marginalzone B-celllymphomas: correlationwithclinic CR - alparameters andflowcytometry in 120 patients. AnnOncol 2009;20:129- CR - Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, BryonPA, CR - et al. Non- MALT marginalzone B-celllymphomas: a description of CR - clinicalpresentationand outcome in 124 patients. Blood 2000;95:1950- CR - Kaynaklar UR - https://dergipark.org.tr/tr/pub/johr/article/123744 L1 - https://dergipark.org.tr/tr/download/article-file/105564 ER -